Michael Sullivan has represented both publicly and privately held companies in a broad range of complex transactions including public offerings and private placements of equity and debt securities, tender offers, venture financings, joint ventures, mergers, stock purchases, and asset purchases. Michael has also represented investment banks in public financing transactions and private equity funds in various mergers and acquisitions.
Recent Speaking Engagements
Michael regularly speaks and presents on M&A topics for the San Diego Chapter of Association of Corporate Counsel
Experience
Michael has experience in a variety of industries, including the life sciences, energy , and technology sectors. His experience includes representing:
Life Sciences
ChemoCentryx, Inc., a biopharmaceutical company targeting the chemokine and chemoattractant systems to discover, develop, and commercialize orally administered therapies, in its acquisition by Amgen for approximately US$3.7 billion
Bionomics Limited, a clinical-stage biopharmaceutical company, in its US initial public offering on the Nasdaq Stock Market
Connect Biopharma, a clinical-stage biopharmaceutical company, in its initial public offering on the Nasdaq Stock Market
Prometheus Biosciences, a clinical-stage biopharmaceutical company, in its US initial public offering on the Nasdaq Stock Market
The underwriters in the initial public offering and listing of Adagene on the Nasdaq Stock Market
The underwriters in the initial public offering and listing of Progenity on the Nasdaq Stock Market
The underwriters in the initial public offering and listing of Alphamab Co., Ltd., a leading biopharmaceutical company dedicated to global development of innovative biologics for cancer therapy, on the Main Board of The Stock Exchange of Hong Kong
Ambrx, a biopharmaceutical company engaged in the discovery, development, and commercialization of protein-based drugs, in its sale to a consortium of Chinese companies
Ignyta, Inc., a precision medicine oncology company, in its acquisition by Roche for approximately US$1.7 billion
Evelo Biosciences, in its acquisition of Epiva Biosciences
Agility Clinical, a contract research organization, in its acquisition by Precision Medicine Group
Advantar Laboratories, a contract analytical laboratory specializing in pharmaceutical research, development and clinical packaging, in its sale to Eurofins Scientific
Ellipse Technologies, a developer of minimally invasive treatments for spinal deformities, in its US$410 million sale to NuVasive
Aratana Therapeutics, in its acquisition of Okapi Sciences, N.V., a Belgian veterinary medicine company
Somaxon Pharmaceuticals in its acquisition by Pernix
Aratana Therapeutics in its acquisition of Vet Therapeutics, a veterinary medicine company
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, in its initial public offering on the NASDAQ Global Select Market
Prometheus Laboratories, Inc., a marketer and promoter of pharmaceutical products and complementary diagnostic testing services, in its acquisition by Nestlé Health Science US Holdings, Inc.
Tacere Therapeutics in its acquisition by Benitec
Kalypsys Inc., in its asset sale to Wako Pure Chemicals Industries
Life Technologies Corporation in its acquisition of Biotrove, Inc.
Cabrellis Pharmaceuticals in its spinout from Conforma Therapeutics
Conforma Therapeutics in its acquisition by Biogen Idec
US$551 million disposition of a portfolio of renewable energy generation and storage assets to American Electric Power
US$1.540 billion disposition of a portfolio of renewable energy generation and storage assets to Consolidated Edison Inc.
US$387 million disposition of natural gas utilities in Mississippi and Alabama
US$875 million acquisition of AEI’s stake in two South American utilities jointly owned with AEI (named a “Deal of the Year” by both LatinFinance and EuroMoney)
Acquisition, through its Energy South, Inc. subsidiary, of Willmut Gas & Oil Company, a natural gas distribution company
US$2.875 billion January 2018 forward sale and common stock transaction
US$1.725 billion January 2018 Series A 6% Mandatory Convertible Preferred Stock offering
US$5.000 billion January 2018 fixed and floating rate notes offering
US$1.265 billion July 2018 forward sale and common stock transaction
US$575 million July 2018 Series B 6.75% Mandatory Convertible Preferred Stock offering
US$700 million June 2019 5.750% Junior Subordinated Notes offering
US$900 million June 2020 Series C, 4.875% Fixed-Rate Reset Cumulative Redeemable Perpetual Preferred Stock offering
US$400 million November 2024 6.625% Fixed-to-Fixed Reset Rate Junior Subordinated Notes offering
US$600 million November 2024 6.550% Fixed-to-Fixed Reset Rate Junior Subordinated Notes offering
San Diego Gas & Electric Company in its:
US$400 million May 2018 4.15% Series SSS First Mortgage Bond offering
US$400 million May 2019 4.100% Series TTT First Mortgage Bond offering
US$400 million March 2020 3.320% Series UUU First Mortgage Bond offering
US$800 million September 2020 4.100% Series VVV First Mortgage Bond offering
US$750 million August 2021 2.950% Series WWW Green First Mortgage Bond offering
US$500 million March 2022 3.100% Series XXX First Mortgage Bond offering
US$500 million March 2022 3.700% Series YYY First Mortgage Bond offering
US$800 million March 2023 5.350% Series YYY First Mortgage Bond offering
US$600 million August 2023 2.950% Series AAAA Green First Mortgage Bond offering
US$600 million August 2023 5.550% Series BBBB First Mortgage Bond offering
US$600 million March 2024 5.550% Series CCCC First Mortgage Bond offering
Southern California Gas Company in its:
US$400 million May 2018 4.125% Series UU First Mortgage Bond offering
US$400 million August 2018 4.3% Series VV First Mortgage Bond offering
US$350 million May 2019 3.95% Series WW First Mortgage Bond offering
US$650 million January 2020 2.55% Series XX First Mortgage Bond offering
US$300 million September 2020 Floating Rate Notes offering
US$700 million September 2022 2.950% Notes offering
US$600 million November 2022 6.350% Series YY Green First Mortgage Bond offering
US$500 million May 2023 5.200% Series ZZ First Mortgage Bond offering
US$500 million May 2023 5.200% Series AAA First Mortgage Bond offering
US$500 million March 2024 5.600% Series BBB First Mortgage Bond offering
US$600 million August 2024 5.050% Series CCC First Mortgage Bond offering
Portland General Electric, the largest utility company in the State of Oregon, in its:
US$430 million August 2022 forward sale and common stock transaction
US$300 million April 2023 at-the-market offering program and related forward sale
Infraestructura Energética Nova (IEnova), one of the largest private energy companies in Mexico and the first energy company to list shares on the Mexican Stock Exchange, in its:
US$598 million global initial public offering, including a private placement of the shares in the United States and outside Mexico
US$852 million acquisition of the 252-MW Ventika wind power generation facilities – named a “Deal of the Year” by Latin Finance
US$1.600 billion follow-on equity offering, the largest equity offering in Latin America in 2016 – named a “Deal of the Year” by LatinFinance
US$840 million dual-tranche sale, the companies’ debut offering on the international debt capital markets
NRG Solar, a subsidiary of NRG, which owns or has partial investment in more than 150 renewable energy projects totaling approximately 4,500-MW (AC) of solar and wind capacity in operation throughout North America, in its acquisition of:
Spanish Town Estate Solar 1, a 4,998-kW DC solar generation project being developed in St. Croix, US Virgin Islands
Kansas South Solar Project, a 20-MW (AC) solar project of Recurrent Energy, a provider of alternative energy resource
Guam Solar Project, a 25.65-MW (AC) solar project of Quantum Guam Power Holdings, a provider of alternative energy resources
Michael also has advised corporate clients on a wide range of general corporate matters, including: recapitalizations, fund formation, securities law, stock market listing obligation compliance issues, and entity formations.
Qualifications
Bar Qualification
California
Education
JD, Northwestern University School of Law, 1999 Executive Board, Northwestern Law Review, Order of the Coif
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.
